"First line" trang 1 - tải miễn phí từ tailieunhanh
Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results
10    42    1
Study on prevalance of drug resistance and genetic mutation for drug resistance HIV on HIV/AIDS patients with first line antiretroviral treatment failure at Dongda hospital Ha Noi

Study on prevalance of drug resistance and genetic mutation for drug resistance HIV on HIV/AIDS patients with first line antiretroviral treatment failure at Dongda hospital Ha Noi
8    112    0
Assessing the psychometric properties and the perceived usefulness of the BasisRaadsOnderzoek (BARO) as a first-line screening instrument for juvenile offenders

Assessing the psychometric properties and the perceived usefulness of the BasisRaadsOnderzoek (BARO) as a first-line screening instrument for juvenile offenders
7    89    0
Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
10    77    0
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
7    65    1
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
6    31    1
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and postpazopanib era: A meta-analytic evaluation

Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and postpazopanib era: A meta-analytic evaluation
9    62    2
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
11    76    1
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial
9    51    1
Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatinradiotherapy in locally advanced nasopharyngeal carcinoma: Preliminary results of a prospective phase II trial

Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatinradiotherapy in locally advanced nasopharyngeal carcinoma: Preliminary results of a prospective phase II trial
9    48    1
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
9    41    1
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study
10    64    1
Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: A randomized phase II study
7    52    1
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/ bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/ bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)
10    50    1
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
6    54    1
Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study

Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study
17    36    1
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
8    45    1
Evaluation of the efficiency of tenofovir + lamivudine + lopinavir ritonavir regimen in HIV/AIDS patients with first line treatment failure in Hai Phong (6/2012 - 6/2019)

Evaluation of the efficiency of tenofovir + lamivudine + lopinavir ritonavir regimen in HIV/AIDS patients with first line treatment failure in Hai Phong (6/2012 - 6/2019)
6    34    1
The relationship between T-CD4 recovery and HIV disclosure status among HIV-infected patients on first-line antiretroviral therapy at the Hospital for Tropical Diseases in Ho Chi Minh City

The relationship between T-CD4 recovery and HIV disclosure status among HIV-infected patients on first-line antiretroviral therapy at the Hospital for Tropical Diseases in Ho Chi Minh City
7    51    1
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: Study protocol of a randomized, open-label, multicentric study

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: Study protocol of a randomized, open-label, multicentric study
9    1    1